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In 1874, Francis Galton, a cousin of
Charles Darwin, coined the idiom “nature
and nurture” to cover all of the influences
that determine an adult’s constitution—
the sum total of their particular physical
and behavioral characteristics. In this is-
sue of the Journal, Shrestha et al. [1] ap-
ply state-of-the-art genetics along with
explicit modeling of an “environmental”
component (high risk exposure) to dis-
entangle the nature and nurture of an
individual’s susceptibility to HIV-1. The
study is an example of the rapidly evolving
field of host genetics in infectious diseases.
Nature offers 2 experiments on HIV-1
susceptibility: the uniqueness of long-term
nonprogressors and the highly exposed
uninfected individual. Both represent sit-
uations that hide a large amount of het-
erogeneity in mechanisms and biology.
However, the condition of being “exposed
uninfected” appears to be particularly in-
tractable, because it grafts a multifactorial
trait onto the poor efficiency of transmis-
sion of HIV-1 and the rarity of cohorts of
individuals that are characterized as high-
ly exposed and persistently seronegative.
Particular studies have examined hetero-
sexual couples with discordant HIV sero-
status, highly exposed sex workers, and
highly exposed men having sex with men.
The mechanisms identified or invoked to
modulate susceptibility to infection in the
various reports emphasize the relevance of
differences in acquired immunity, through
the role of protective cytotoxic T lympho-
cyte responses and NK cell activity in the
context of specific HLA class I alleles (re-
viewed in [2]), as well as differences in
humoral responses at mucosal surfaces [3].
The other area of research has included
assessment of expression of chemokine
receptors and their ligands, as well as the
role of genetic variants of those molecules
(reviewed in [2]). In addition, CD4 T
cells from healthy blood donors differ
markedly in their susceptibility to HIV-
1 infection [4], and a relative resistance
to HIV-1 infection of CD4 T cells from
exposed uninfected individuals has been
described [5].
The study by Shrestha et al. [1] aimed
at freeing itself from the constraint of the
low numbers of the above unique pop-
ulations—and, thus, the constraint of
limited statistical power—by using a
standardized cumulative risk exposure
measurement on a larger number of in-
dividuals ( ). They applied thisnp 789
approach to the evaluation of genetic var-
iants of 9 genes involved in HIV-1 entry
and replication, with a focus on the bi-
ology of CCR5-mediated pathways. Not
included was CCL3L1, coding for the
CCR5 ligand macrophage inflammatory
protein 1 (MIP1)–a-P and present in the
human genome at variable copy num-
bers, which define different levels of risk
for infection [6].
Most genetic epidemiology studies to
date have been unable to deal efficiently
with environmental factors [7]. Although
taking genetic “measurements” (i.e., ge-
notyping) is straightforward, measuring
environmental exposures can be difficult
and imprecise. Usually, we have to rely on
traditional epidemiological methods (e.g.,
questionnaires), with all of their short-
comings. Shrestha et al. use an innova-
tive approach to incorporate a multivar-
iate propensity score for cumulative high
risk exposure. Propensity methods were
originally developed to estimate which pa-
rameters are associated with the “risk” of
receiving a specific treatment in nonran-
domized databases [8]. Patients may have
had different reasons for being given one
or another treatment, and propensity mod-
els offered a way to balance the compar-
ison of these treatments for such uneven
treatment preferences. In the genetic set-
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ting, genotypes are the equivalent of
“treatments.” Typically, we rely on Men-
delian randomization [9] and assume
that high risk exposure and confounding
factors would also be randomly assigned
to different genotypes. This means that
we accept that exposure would be simi-
lar regardless of genotype. One could go
even a step further and examine whether
there is any interaction between risk ex-
posure and genetic profile. However, dem-
onstration of interaction effects would re-
quire even larger sample sizes.
There are more challenges to be over-
come in modeling environmental factors.
Multivariate models have shortcomings,
and predictive models also need valida-
tion, both internally (through bootstrap-
ping, for example) and externally (in dif-
ferent populations). There is increasing
evidence of the limitations of appraising
prognostic factors [10]. Moreover, the dis-
criminatory ability of predictive models
may still be limited, even if several risks
are considered. For example, even in Shres-
tha et al.’s state-of-the-art study, the high-
risk quintile, compared with the low-risk
quintile, had only a 2-fold difference in risk
(49% vs. 24%).
Even if we ignore the complexity con-
ferred by the interaction of the host ge-
netic background with risk behavior, the
sample size required to detect modest ge-
netic effects (i.e., odds ratios in the 1.1–
1.8 range) can be quite large. Most genet-
ic epidemiology studies conducted in the
past have been underpowered [11]. An ad-
vantage of the study by Shrestha et al. is
that, given its sample size, modest genetic
effects for relatively common alleles would
not be missed. However, even with 789
subjects, there is not enough power to pur-
sue polymorphisms with allele frequen-
cies !10%. It is unknown how much such
uncommon polymorphisms contribute to
the genetic background of HIV-1 suscep-
tibility. For example, the strongest pro-
tective factor known to date, homozy-
gosity for the CCR5-D32 allele, occurs in
only 1% of white individuals and is prac-
tically absent in people of African descent.
Multiple testing can also lead to spu-
rious findings that are not validated by
subsequent studies [12]. Of the 50 poly-
morphisms tested by Shrestha et al., 2 or
3 would be expected to show signifi-
cant associations ( ) just by chance.P ! .05
With the advent of discovery-oriented
approaches [13], it is possible to screen
hundreds of thousands of genetic vari-
ants across relatively large data sets. At
first pass, a typical whole-genome asso-
ciation study may yield a few thousand
“promising” polymorphisms for any com-
plex trait. Evidently, all of these tentative
associations need further validation in
independent data sets. Thus, proposed
genetic associations should be considered
to be works in progress [14]. Haplotype
analyses, such as those utilized by Shres-
tha et al., are also becoming the rule. The
HapMap project [15] aims to describe
most existing genetic variability by typing
only a limited number of polymorphisms
per gene. However, haplotypes may not
always adequately represent the full var-
iability in diverse populations, and com-
paring selected haplotypes rather than all
possible haplotypes without clear justi-
fication is a dangerous practice.
Another major threat to the validity of
genetic epidemiology studies is the selec-
tive publication and selective reporting of
the analyses being performed. Shrestha et
al. provide an excellent example of how
all tested polymorphism associations should
be reported, regardless of whether they
lead to significant results. The availability
of electronic online supplements should
obviate problems related to the mass of
currently assembled databases, even for
the most data-rich analyses. In publica-
tions that present the discovery of a few
formally statistically significant associa-
tions, it is unknown whether the inves-
tigators tested many others but are re-
porting only the most significant ones.
Such selective reporting may lead to a
distorted literature, and replication of the
claimed findings would be uncommon
[12]. Formal statistical significance should
not be used as a criterion for dissemination
of research in genetic epidemiology.
Finally, we still need more empirical evi-
dence on how to link epidemiological evi-
dence with data on the biological and
functional significance of postulated gene-
disease associations [16]. Of the 4 candi-
date protective polymorphisms identified
by Shrestha et al., one is in a noncoding
region, another is synonymous (no amino
acid change), and a third is at odds with
previous reports. Only 1 polymorphism,
CCR2 64I, has a biological rationale to
support its role [17] and concurrent evi-
dence for protection against disease pro-
gression [18]. Nevertheless, this polymor-
phism has not been associated with risk
of HIV-1 transmission via the vertical route
[19]. Squaring epidemiology with biology
can be difficult. However, we should keep
an open mind, since there is much we do
not know about the intricacies of the hu-
man genome and its function. For example,
polymorphisms in noncoding regions may
have important indirect biological effects.
Overall, the extensive work of Shrestha
et al. yielded a modest output—4 “hits”
among 50 genetic variants in 9 genes. Is
this a satisfactory outcome for a large and
costly experiment? The answer is a sober
“yes.” Sooner or later, all genes linked to
the pathogenesis of a given disease will be
genotyped, and all putative genetic mark-
ers (associated with a study phenotype)
will be followed by using the appropriate
genetic tools to identify linked functional
variants, by establishing the appropriate
biological experiments, and by validation
across several populations and cohorts.
For susceptibility to HIV-1 infection, the
list of candidates is long, because limited
work has been done on variants of genes
that are needed for viral replication in the
cell [20, 21]. The list is longer if we move
from acquired immunity to the innate
immunity or to genes coding for cellu-
lar antiretroviral defense mechanisms.
Species-specific single–amino acid dif-
ferences in apolipoprotein B mRNA-ed-
iting enzyme, catalytic polypeptide-like
3G (APOBEC3G) [22, 23], associated
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with hypermutation of the viral DNA,
and in tripartite motif–containing pro-
tein 5 (TRIM5)–a [24, 25], an antiret-
roviral protein acting after HIV-1 infects
the cell, are enough to provide adequate
protection against HIV-1 in some pri-
mates, whereas the human versions are
ineffective. Characterization of variants
of these genes in humans has just started
[26, 27].
Against a background of “hype” and
excitement around all things genomic,
there is one more lesson to learn from
most studies trying to make sense of the
complex biology behind interindividual
differences. It is true that some “big” dis-
coveries and breakthroughs will happen.
For example, the identification of the
CCR5-D32 mutation not only resulted in
a paradigm shift in our understanding of
pathogenesis, but it also helped in the
development of a new class of antiret-
roviral agents. However, much work in
genetics and genomics is unavoidably
antlike, going through scores of data to,
piece by piece, reconstruct the pathogen-
host interaction—this time, starting from
the host side. It is unlikely that the iden-
tification of multigene effects will change
the management of HIV-1 disease in the
near future. It would even be erroneous
to suggest that genetic tests that, in iso-
lation, confer small quanta of informa-
tion should be integrated into patient
care. One has to verify first that they are
indeed true and reproducible, possible to
standardize for clinical use, amenable to
use by information-overwhelmed clini-
cians, readily interpretable, able to im-
prove outcomes, and cost-effective. None
of the validated or postulated genetic
markers of HIV-1 disease susceptibility
or progression meets all of these criteria
for clinical use.
How should infectious-diseases spe-
cialists react to the growing number of
studies on host genetics? Over the past 20
years, they have been asked to learn a great
deal of microbiology, then basic immu-
nology, molecular biology, and biostatis-
tics. Now they will need to learn genetics
and genetic nomenclature and to build ge-
netic cohorts [28] and collaborations be-
tween cohorts working on the same field
[29]. Large challenges lie ahead.
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